Cancer Letters, 44 (1989) 237—240
Elsevier Scientific Publishers Ireland Ltd.

Subject Index

Volume 44

adenovirus type 12, E1A gene, diacylglycerol, cytotoxicity, anticancer drug, 143
aflatoxin B_1, vitamin A, microsomal activation, DNA adduct, glutathione conjugation, 83
AKR mice, cyclophosphamide, carcinogenicity, NMRI mice, genetic susceptibility, 221
alcohol, nitrosation, nitration, tryptophol, mutagens, 109
altered hepatic foci, ciprofibrate, peroxisome, hepatocarcinogenesis, 95
anti-laminin antibodies, glioblastoma, cell lines, intraocular transplantation, intracerebral transplantation, glial fibrillary acidic protein, 151
anticancer drug, adenovirus type 12, E1A gene, diacylglycerol, cytotoxicity, 143
anticancer porphyrins, photosensitization, LDL, transformed fibroblasts, 157
antifolate, serine, myeloma, chemotherapy, thymidylate, nucleotide biosynthesis, 217
antioxidants, fecapentaene-12, HPLC-analysis, 33
antiproliferative action, pancreatic adenocarcinoma, coculture, PaTu II, auranofin, chloroquine, 61
antiproliferative effect, retinoic acid, interferon, 55
areca-nut derived nitrosamines, *N*-nitrosoguavacine, *N*-nitrosoguvacoline, urinary metabolites, *N*-nitrosonipecotic acid, 211
auranofin, pancreatic adenocarcinoma, antiproliferative action, coculture, PaTu II, chloroquine, 61

B16 melanoma, hypoxia, metrizamide, misonidazole, 185
biliverdin, cell culture, liver tumor promotion, phenobarbital, oncongenes expression, 191
breast cancer, oestradiol, oestrone, oestradiol 17β-hydroxysteroid dehydrogenase, 45

cAMP, vitamin E, differentiation, 17
carboplatin, hyperthermia, cytotoxicity, 205
carcinogenesis, *N*-nitrosodiethylamine, riboflavin, flavin co-enzymes, 167
carcinogenesis, transplacental, in vitro, tobacco-specific, fetal, respiratory tract, 173
carcinogenicity, cyclophosphamide, AKR mice, NMRI mice, genetic susceptibility, 221
cellular uptake, photodynamic therapy, lipophilicity, phthalocyanines, 7
cell culture, liver tumor promotion, phenobarbital, biliverdin, oncongenes expression, 191
cell lines, glioblastoma, intraocular transplantation, intracerebral transplantation, glial fibrillary acidic protein, anti-laminin antibodies, 151
chemotherapy, serine, myeloma, antifolate, thymidylate, nucleotide biosynthesis, 217
chloroquine, pancreatic adenocarcinoma, antiproliferative action, coculture, PaTu II, auranofin, 61
ciprofibrate, peroxisome, altered hepatic foci, hepatocarcinogenesis, 95
coculture, pancreatic adenocarcinoma, antiproliferative action, PaTu II, auranofin, chloroquine, 61
colony formation, combination effects, interferon, cytoxic agent, melanoma, hypernephroma, 49
colon antigens, monoclonal antibodies, human adenocarcinoma, 127
Colo 26 carcinoma, phthalocyanines, tumour site, 73
combination effects, interferon, cytoxic agent, colony formation, melanoma, hypernephroma, 49
cyclophosphamide, carcinogenicity, AKR mice, NMRI mice, genetic susceptibility, 221
cytochrome *P*-450, esophageal carcinoma, methylbenzylnitrosamine, 39
cytotoxicity, adenovirus type 12, E1A gene, diacylglycerol, anticancer drug, 143
cytotoxicity, hyperthermia, carboplatin, 205
cytoxic agent, combination effects, interferon, colony formation, melanoma, hypernephroma, 49

diacylglycerol, adenovirus type 12, E1A gene, cytotoxicity, anticancer drug, 143
dietary fat, mammary tumors, metastasis, linoleic acid, 117
differentation, plasminogen activator, plasminogen activator inhibitor, urokinase, tissue-type PA, neuroblastoma, neurite outgrowth, 101
differentiation, melanoma, natural killer cell sensitivity, metastasis, growth rate, 67
differentiation, vitamin E, cAMP, 17
DNA adduct, vitamin A, microsomal activation, aflatoxin B_1, glutathione conjugation, 83

E1A gene, adenovirus type 12, diacylglycerol, cytotoxicity, anticancer drug, 143
Ehrlich ascitic carcinoma, liver mitochondria, proteinase, 179
esophageal carcinoma, methylbenzylnitrosamine, cytochrome *P*-450, 39
ethyl- and isopropyl methanesulfonate, thymic lymphoma induction, 199

fecapentaene-12, antioxidants, HPLC-analysis, 33
fetal, transplacental, carcinogenesis, in vitro, tobacco-specific, respiratory tract, 173
flavin co-enzymes, carcinogenesis, *N*-nitrosodiethylamine, riboflavin, 167

genetic susceptibility, cyclophosphamide, carcinogenicity, AKR mice, NMRI mice, 221
glial fibrillary acidic protein, glioblastoma, cell lines, intraocular transplantation, intracerebral transplantation, anti-laminin antibodies, 151
glioblastoma, cell lines, intraocular transplantation, intracerebral transplantation, glial fibrillary acidic protein, anti-laminin antibodies, 151
glutathione conjugation, vitamin A, microsomal activation, aflatoxin B_1, DNA adduct, 83
glutathione *S*-transferases, hamsters, inducers, tetrachlorodibenzo-*p*-dioxin 2,3,7,8-, phenobarbital, *trans*-stilbene oxide, 89
growth rate, melanoma, natural killer cell sensitivity, differentiation, metastasis, 67

hamsters, inducers, glutathione *S*-transferases, tetrachlorodibenzo-*p*-dioxin 2,3,7,8-, phenobarbital, *trans*-stilbene oxide, 89
hepatocarcinogenesis, ciprofibrate, peroxisome, altered hepatic foci, 95
HPLC-analysis, fecapentaene-12, antioxidants, 33
human adenocarcinoma, monoclonal antibodies, colon antigens, 127
human melanoma, metastic variants, methionine metabolism, 23
hypernephroma, combination effects, interferon, cytoxic agent, colony formation, melanoma, 49
hyperthermia, carboplatin, cytotoxicity, 205
hypoxia, B16 melanoma, metrizamide, misonidazole, 185

inducers, hamsters, glutathione *S*-transferases, tetrachlorodibenzo-*p*-dioxin 2, 3, 7, 8-, phenobarbital, *trans*-stilbene oxide, 89
interferon, combination effects, cytoxic agent, colony formation, melanoma, hypernephroma, 49
interferon, retinoic acid, antiproliferative effect, 55
intracerebral transplantation, glioblastoma, cell lines, intraocular transplantation, glial fibrillary acidic protein, anti-laminin antibodies, 151
intraocular transplantation, glioblastoma, cell lines, intracerebral transplantation, glial fibrillary acidic protein, anti-laminin antibodies, 151
in vitro, transplacental, carcinogenesis, tobacco-specific, fetal, respiratory tract, 173

LDL, photosensitization, anticancer porphyrins, transformed fibroblasts, 157
linoleic acid, dietary fat, mammary tumors, metastasis, 117
lipophilicity, photodynamic therapy, cellular uptake, phthalocyanines, 7
liver mitochondria, proteinase, Ehrlich ascitic carcinoma, 179
liver tumor promotion, cell culture, phenobarbital, biliverdin, oncongenes expression, 191

mammary tumors, dietary fat, metastasis, linoleic acid, 117
melanoma, combination effects, interferon, cytoxic agent, colony formation, hypernephroma, 49
melanoma, natural killer cell sensitivity, differentiation, metastasis, growth rate, 67
membrane phosphorylation, tumor inhibitor, oncogene expression, 227
metastasis, dietary fat, mammary tumors, linoleic acid, 117
metastasis, melanoma, natural killer cell sensitivity, differentiation, growth rate, 67
metastic variants, human melanoma, methionine metabolism, 23
methionine metabolism, human melanoma, metastic variants, 23
methylbenzylnitrosamine, esophageal carcinoma, cytochrome *P*-450, 39
metrizamide, hypoxia, B16 melanoma, misonidazole, 185
mice, naloxone, murine melanoma, 137
microsomal activation, vitamin A, aflatoxin B_1, DNA adduct, glutathione conjugation, 83
misonidazole, hypoxia, B16 melanoma, metrizamide, 185
monoclonal antibodies, colon antigens, human adenocarcinoma, 127
murine melanoma, naloxone, mice, 137
mutagens, nitrosation, nitration, tryptophol, alcohol, 109
myeloma, serine, chemotherapy, antifolate, thymidylate, nucleotide biosynthesis, 217

N-nitrosodiethylamine, carcinogenesis, riboflavin, flavin co-enzymes, 167
N-nitrosoguavacine, areca-nut derived nitrosamines, *N*-nitrosoguvacoline, urinary metabolites, *N*-nitrosonipecotic acid, 211
N-nitrosoguvacoline, areca-nut derived nitrosamines, *N*-nitrosoguavacine, urinary metabolites, *N*-nitrosonipecotic acid, 211
N-nitrosonipecotic acid, areca-nut derived nitrosamines, *N*-nitrosoguavacine, *N*-nitrosoguvacoline, urinary metabolites, 211
naloxone, murine melanoma, mice, 137
natural killer cell sensitivity, melanoma, differentiation, metastasis, growth rate, 67
neurite outgrowth, plasminogen activator, plasminogen activator inhibitor, urokinase, tissue-type PA, neuroblastoma, differentation, 101
neuroblastoma, plasminogen activator, plasminogen activator inhibitor, urokinase, tissue-type PA, differentation, neurite outgrowth, 101
nitration, nitrosation, tryptophol, mutagens, alcohol, 109
nitrosation, nitration, tryptophol, mutagens, alcohol, 109
NMRI mice, cyclophosphamide, carcinogenicity, AKR mice, genetic susceptibility, 221
nucleotide biosynthesis, serine, myeloma, chemotherapy, antifolate, thymidylate, 217

oestradiol, breast cancer, oestrone, oestradiol 17β-hydroxysteroid dehydrogenase, 45
oestradiol 17β-hydroxysteroid dehydrogenase, breast cancer, oestradiol, oestrone, 45
oestrone, breast cancer, oestradiol, oestradiol 17β-hydroxysteroid dehydrogenase, 45
oncogene expression, tumor inhibitor, membrane phosphorylation, 227
oncongenes expression, cell culture, liver tumor promotion, phenobarbital, biliverdin, 191

pancreatic adenocarcinoma, antiproliferative action, coculture, PaTu II, auranofin, chloroquine, 61
PaTu II, pancreatic adenocarcinoma, antiproliferative action, coculture, auranofin, chloroquine, 61
peroxisome, ciprofibrate, altered hepatic foci, hepatocarcinogenesis, 95
phenobarbital, cell culture, liver tumor promotion, biliverdin, oncongenes expression, 191
phenobarbital, hamsters, inducers, glutathione *S*-transferases, tetrachlorodibenzo-*p*-dioxin 2,3,7,8-, *trans*-stilbene oxide, 89
photodynamic therapy, cellular uptake, lipophilicity, phthalocyanines, 7
photodynamic therapy, porphycenes, tumour localization, photosensitization, 1
photosensitization, anticancer porphyrins, LDL, transformed fibroblasts, 157
photosensitization, porphycenes, tumour localization, photodynamic therapy, 1
phthalocyanines, photodynamic therapy, cellular uptake, lipophilicity, 7
phthalocyanines, tumour site, Colo 26 carcinoma, 73
plasminogen activator, plasminogen activator inhibitor, urokinase, tissue-type PA, neuroblastoma, differentation, neurite outgrowth, 101
plasminogen activator inhibitor, plasminogen activator, urokinase, tissue-type PA, neuroblastoma, differentation, neurite outgrowth, 101
porphycenes, tumour localization, photosensitization, photodynamic therapy, 1
proteinase, liver mitochondria, Ehrlich ascitic carcinoma, 179

respiratory tract, transplacental, carcinogenesis, in vitro, tobacco-specific, fetal, 173
retinoic acid, interferon, antiproliferative effect, 55
riboflavin, carcinogenesis, cfriN-nitrosodiethylamine, flavin co-enzymes, 167

serine, myeloma, chemotherapy, antifolate, thymidylate, nucleotide biosynthesis, 217

tetrachlorodibenzo-*p*-dioxin 2,3,7,8-, hamsters, inducers, glutathione *S*-transferases, phenobarbital, *trans*-stilbene oxide, 89
thymic lymphoma induction, ethyl- and isopropyl methanesulfonate, 199
thymidylate, serine, myeloma, chemotherapy, antifolate, nucleotide biosynthesis, 217
tissue-type PA, plasminogen activator, plasminogen activator inhibitor, urokinase, neuroblastoma, differentation, neurite outgrowth, 101
tobacco-specific, transplacental, carcinogenesis, in vitro, fetal, respiratory tract, 173
trans-stilbene oxide, hamsters, inducers, glutathione *S*-transferases, tetrachlorodibenzo-*p*-dioxin 2,3,7,8-, phenobarbital, 89
transformed fibroblasts, photosensitization, anticancer porphyrins, LDL, 157
transplacental, carcinogenesis, in vitro, tobacco-specific, fetal, respiratory tract, 173
tryptophol, nitrosation, nitration, mutagens, alcohol, 109

tumor inhibitor, membrane phosphorylation, oncogene expression, 227
tumour localization, porphycenes, photosensitization, photodynamic therapy, 1
tumour site, phthalocyanines, Colo 26 carcinoma, 73

urinary metabolites, areca-nut derived nitrosamines, *N*-nitrosoguavacine, *N*-nitrosoguvacoline, *N*-nitrosonipecotic acid, 211
urokinase, plasminogen activator, plasminogen activator inhibitor, tissue-type PA, neuroblastoma, differentation, neurite outgrowth, 101

vitamin A, microsomal activation, aflatoxin B_1, DNA adduct, glutathione conjugation, 83
vitamin E, cAMP, differentiation, 17

Cancer Letters, 44 (1989) 241—242
Elsevier Scientific Publishers Ireland Ltd.

Author Index

Volume 44

Aboobaker, V.S. 83,167

Barch, D.H. 39
Bartsch, H. 211
Benjamin, L.A. 101
Berg, K. 7
Berger, M.R. 221
Bhattacharya, R.K. 83, 167
Bigda, J. 67
Biolo, R. 1
Bomirski, A. 67
Bommer, J.C. 7
Braunsteiner, H. 49
Brune, K. 61

Candide, C. 157
Castonguay, A. 173
Chan, W.-S. 73
Clark, T.D. 95
Cohen, J.D. 205
Collins, V.P. 151
Csaikl, F. 227
Csaikl, U. 227

Daxenbichler, G. 55
Denz, H.A. 49
Dubertret, L. 157

Erickson, K.L. 117

Fornabaio, D.M. 185
Fox, C.C. 39
Frayssinet, C. 191
Friesen, M. 211
Fujinaga, K. 143

Gastl, G. 49
Ghilchik, M.W. 45
Glauert, H.P. 95
Goldstein, S. 157
Granholm, L. 151
Gregus, Z. 89
Guardiano, M. 1

Hageman, G.J. 33
Hart, D.A. 101
Hart, I.R. 73
Huang, K. 127
Hubbard, N.E. 117

James, V.H.T. 45
Jori, G. 1
Joshi, P.A. 173

Kim, Y.S. 185
Kimura, G. 143
Kirchebner, P. 55
Klassen, C.D. 89
Kleinjans, J.C.S. 33
Kmieć, Z. 67

Lafarge-Frayssinet, C. 191
Lechleitner, M. 49
Letnansky, K. 227
Liteplo, R.G. 23

Madhu, C. 89
Marshall, J.F. 73
Marth, C. 55
Mathiesen, T. 151
Matsuzaki, A. 143
Mazière, C. 157
Mazière, J.C. 157
McConnell, B. 109
McGarry, R.C. 101
Medina, M.A. 179
Moan, J. 7
Mollenhauer, J. 61
Moosic, J.P. 127
Morlière, P. 157
Mosley, A.M. 127
Mower, H.F. 109
Murgo, A.J. 137
Myśliwska, J. 67
Myśliwska, A. 67

Nachbaur, D.M. 49
Niemczura, W.P. 109

Núñez De Castro, I. 179
Ohshima, H. 211
Ohtsu, M. 143
Olson, L. 151
Onodera, K. 143

Petru, E. 221
Pluijmen, M.H.M. 33
Prabhu, A.L. 83
Prasad, K.C. 17

Reed, M.J. 45
Reyftmann, J.P. 157
Riches, D. 217
Robins, H.I. 205
Rossignol, G. 173

Sánchez-Jiménez, F. 179
Santus, R. 157
Schaffner, K. 1
Schmähl, D. 221
Schmitt, C.L. 205
Schuller, H.M. 173
Segal, A. 199
Sellakumar, A. 199
Shimura, H. 143
Shiroki, K. 143
Singh, A. 45
Snell, K. 217
Stackpole, C.W. 185

Tanaka, K. 109
Taylor, C.W. 127
Thaler, J. 49

Urdiales, J.L. 179

Verhagen, H. 33

Witkowski, J. 67

Yeoman, L.C. 127

Zeilhofer, H.U. 61